Trial Profile
Penetration of Arbekacin sulfate into epithelial lining fluid(ELF) of patients with pneumonia.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 May 2014
Price :
$35
*
At a glance
- Drugs Arbekacin (Primary)
- Indications Bacterial infections; Pneumonia
- Focus Pharmacokinetics
- 20 Apr 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 12 Jul 2012 New trial record